The primary objectives of this trial are to provide FTC-203 study participants in South Africa with continued access to the study drug, emtricitabine (FTC), following completion of the FTC-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.

Key Inclusion Criteria:

• Complete or have previously completed at least through the Week 96 Visit (i.e., 96 weeks on study) for the FTC-203 study.
• Complete all End-of-Study Visit procedures for the FTC-203 study.
• Either (a) have a plasma HIV-1 RNA viral load of ≤ 400 copies/mL at the End-of-Study Visit for the FTC-203 study, or (b) if the subject's plasma HIV-1 RNA viral load at the End-of-Study Visit for FTC-203 study is > 400 copies/mL, their viral load is < 1.0 log10 above the nadir recorded after Week 8 of the FTC-203 study and there is reliable genotypic evidence showing a lack of resistance to emtricitabine.
• A parent or other legal guardian has provided written informed consent to the subject participating in the rollover protocol. As applicable, based on the subject's age and normal institution practice, the subject should additionally provide their written informed consent or assent to participate in the rollover protocol.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug

Up to 586 Weeks + 30 days

• Safety Analysis Set: all enrolled participants who have received at least 1 dose of study drug
• One participant who resulted in incomplete abortion (System order class: Pregnancy, puerperium and perinatal conditions; Event term: Abortion incomplete) was not counted as part of SAE but was counted under pregnancies.